Business Model StrengthTakara Bio's diversified revenue streams from life sciences products and services provide a stable foundation for long-term growth and resilience.

Balance Sheet HealthA strong balance sheet with low leverage enhances financial stability, allowing Takara Bio to invest in growth opportunities and withstand market volatility.

Industry PositionAs a leader in biotechnology, Takara Bio benefits from a strong market position in genetic engineering and regenerative medicine, supporting long-term growth.

Bears Say

Revenue DeclineDeclining revenue indicates challenges in maintaining market share or product demand, potentially impacting long-term financial performance.

Cash Flow IssuesNegative free cash flow suggests difficulties in funding operations and investments, which could constrain growth and strategic initiatives.

Profitability ConcernsReduced profitability and operating at a net loss highlight operational inefficiencies, affecting the company's ability to generate sustainable earnings.

Takara Bio Inc. News

Takara Bio Board Backs Parent’s Tender Offer, Paving Way for Delisting

Takara Bio Inc. ( ($JP:4974) ) has issued an update. Takara Bio Inc.’s board has endorsed a tender...

5d ago

4974

Takara Bio Deepens Losses, Maintains Full-Year Forecast and Dividend Suspension

Takara Bio Inc. ( ($JP:4974) ) has issued an announcement. Takara Bio Inc. reported nine-month results to December...

5d ago

4974

Takara Bio Swings to Deep Loss, Confirms Forecast and Scraps Dividend

The latest announcement is out from Takara Bio Inc. ( ($JP:4974) ). Takara Bio reported consolidated net sales...

5d ago

4974

Takara Bio Inc. Revises Financial Forecasts Amid Challenging Outlook

An update from Takara Bio Inc. ( ($JP:4974) ) is now available. Takara Bio Inc. announced corrections to...

3M ago

4974

Takara Bio Inc. Reports Decline in Financial Performance

The latest announcement is out from Takara Bio Inc. ( ($JP:4974) ). Takara Bio Inc. reported a decline...

3M ago

4974

Takara Bio Inc. Revises Financial Forecasts and Suspends Dividends Amid Market Challenges

Takara Bio Inc. ( ($JP:4974) ) has shared an update. Takara Bio Inc. has revised its financial forecasts...

3M ago

4974

Takara Bio Inc. Advances Synovial Sarcoma Treatment with New Clinical Study

Takara Bio Inc. (($JP:4974)) announced an update on their ongoing clinical study. Takara Bio Inc. has announced a...

4M ago

4974

Takara Bio Revises Financial Forecasts Amid Market Downturn

The latest update is out from Takara Bio Inc. ( ($JP:4974) ). Takara Bio Inc. has revised its...

4M ago

4974

Takara Bio Inc. Reports Q1 2025 Financial Results and Strategic Expansion

An announcement from Takara Bio Inc. ( ($JP:4974) ) is now available. Takara Bio Inc. reported its consolidated...

6M ago

4974

Takara Bio Inc. Highlights Operational Independence Within Takara Holdings Group

Takara Bio Inc. ( ($JP:4974) ) has provided an announcement. Takara Bio Inc. has announced its relationship with...

8M ago

4974

4974 FAQ

What was Takara Bio Inc.’s price range in the past 12 months?

Takara Bio Inc. lowest stock price was ¥711.00 and its highest was ¥1039.00 in the past 12 months.

What is Takara Bio Inc.’s market cap?

Takara Bio Inc.’s market cap is ¥96.45B.

When is Takara Bio Inc.’s upcoming earnings report date?

Takara Bio Inc.’s upcoming earnings report date is May 07, 2026 which is in 78 days.

How were Takara Bio Inc.’s earnings last quarter?

Takara Bio Inc. released its earnings results on Feb 13, 2026. The company reported -¥22.49 earnings per share for the quarter, missing the consensus estimate of N/A by -¥22.49.

Is Takara Bio Inc. overvalued?

According to Wall Street analysts Takara Bio Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Takara Bio Inc. pay dividends?

Takara Bio Inc. pays a Annually dividend of ¥17 which represents an annual dividend yield of 2.18%. See more information on Takara Bio Inc. dividends here

What is Takara Bio Inc.’s EPS estimate?

Takara Bio Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Takara Bio Inc. have?

Takara Bio Inc. has 120,415,600 shares outstanding.

What happened to Takara Bio Inc.’s price movement after its last earnings report?

Takara Bio Inc. reported an EPS of -¥22.49 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.198%.

Which hedge fund is a major shareholder of Takara Bio Inc.?

Currently, no hedge funds are holding shares in JP:4974

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Takara Bio Inc.

Takara Bio Inc. (4974) is a leading biotechnology company based in Japan, specializing in the development and manufacturing of innovative products and services for the life sciences sector. The company operates primarily in the areas of genetic engineering, gene therapy, and regenerative medicine, providing a range of solutions including reagents, instruments, and services for genomic research, as well as cell and gene therapies. Takara Bio's core products include a variety of molecular biology reagents, CRISPR/Cas9 gene-editing tools, and other biotechnological innovations aimed at advancing research and development in genetics and biotechnology.